Algorae's AI-168 drug shows promise in enhancing heart protection over beta-blockers

Algorae Pharmaceuticals has announced that its new drug candidate, AI-168, shows promise in improving heart protection compared to existing beta-blockers. The drug, which includes cannabidiol, was developed using advanced AI technology and has outperformed beta-blockers in preclinical studies. In tests, AI-168 demonstrated significant improvements in cell proliferation under various stress conditions, achieving up to 94% restoration in certain cell types. The company plans to advance testing from lab studies to animal models to further evaluate AI-168's effectiveness. Additionally, Algorae has identified 24 new drug combinations for cancer treatment, utilizing its AI system. The company has also appointed Dr. Sarah Siggins, a former Johnson & Johnson executive, to its advisory board to enhance its commercial partnerships in AI-generated drug development.